Robinson, R.M.; Reyes, L.; Christopher, B.N.; Duncan, R.M.; Burge, R.A.; Siegel, J.; Nasarre, P.; Wang, P.; O’Bryan, J.P.; Hobbs, G.A.;
et al. A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Antibodies 2024, 13, 101.
https://doi.org/10.3390/antib13040101
AMA Style
Robinson RM, Reyes L, Christopher BN, Duncan RM, Burge RA, Siegel J, Nasarre P, Wang P, O’Bryan JP, Hobbs GA,
et al. A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Antibodies. 2024; 13(4):101.
https://doi.org/10.3390/antib13040101
Chicago/Turabian Style
Robinson, Reeder M., Leticia Reyes, Benjamin N. Christopher, Ravyn M. Duncan, Rachel A. Burge, Julie Siegel, Patrick Nasarre, Pingping Wang, John P. O’Bryan, G. Aaron Hobbs,
and et al. 2024. "A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)" Antibodies 13, no. 4: 101.
https://doi.org/10.3390/antib13040101
APA Style
Robinson, R. M., Reyes, L., Christopher, B. N., Duncan, R. M., Burge, R. A., Siegel, J., Nasarre, P., Wang, P., O’Bryan, J. P., Hobbs, G. A., Klauber-DeMore, N., & Dolloff, N. G.
(2024). A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Antibodies, 13(4), 101.
https://doi.org/10.3390/antib13040101
